Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseasesBrian J. Boyarsky, Julie J. Paik, Jake A. Ruddy et al.|Annals of the Rheumatic Diseases|2021Cited by 186
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseasesJake A. Ruddy, Julie J. Paik, Caoilfhionn M Connolly et al.|Annals of the Rheumatic Diseases|2021Cited by 138
Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following <scp>Two‐Dose SARS</scp>–<scp>CoV</scp>‐2 Messenger <scp>RNA</scp> VaccinationCaoilfhionn M Connolly, Julie J. Paik, Duvuru Geetha et al.|Arthritis & Rheumatology|2021Cited by 116
Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant RecipientsMichael T. Ou, Jacqueline Garonzik‐Wang, Brian J. Boyarsky et al.|Transplantation|2021Cited by 88
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseasesCaoilfhionn M Connolly, Julie J. Paik, Jake A. Ruddy et al.|Annals of the Rheumatic Diseases|2021Cited by 71